As doctors and researchers discover more about the coronavirus, new drugs that could assist in the fight against the virus pop up. Now, a triple-drug combo could be the answer doctors are looking for.
In a new study published in The Lancet journal, it's detailed that three drugs, interferon beta-1b, lopinavir-ritonavir, and ribavirin, have been tested on COVID-19 patients. The researchers divided 127 confirmed COVID-19 patients into two groups, the first group of 86 were given the triple-drug therapy, and the second group of 41 was given the lopinavir-ritonavir combo. All of the patients' cases were mild, and all patients recovered, but what was interesting was the time of recovery and how fast some patients lost COVID-19 symptoms.
The triple-drug group recovered far quicker than the double drug group, as they tested negative for COVID-19 after just 7 days. The double drug group needed a whole 12 days to test negative for the virus. What was also interesting was that patients who had the triple-drug combo lost COVID-19 symptoms much faster, an average of 4 days compared to 8 days. University of California San Francisco's Dr. Peter Chin-Hong said, "This study is really refreshing because it tells us remdesivir isn't the only game in town, and maybe there are other options around. These drugs have a track record of safety."
- > NEXT STORY: Here's the chances of death if you get coronavirus COVID-19 in the US
- < PREVIOUS STORY: Llama's could give humans 'immediate immunity' to the coronavirus